Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andexanet alfa reversal of Enoxaparin in healthy volunteers
NCT03551730Phase 2Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Dec 2012
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of andexanet alfa in hemorrhage (4 arms), sponsored by Portola Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Anti-fXa Activity. Started Dec 2012; status: completed.
02
Drugs
andexanet alfa
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT03551730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551730.